A practical reference on bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
=== Cardiac biomarkers === There are two main cardiac biomarkers used in the assessment of cardiac amyloidosis, troponin and N-terminal proBNP. As expected, with cardiac damage and dysfunction, there can be an elevation of these markers in patients with cardiac amyloidosis. These markers have been incorporated into the various staging/scoring systems used by physicians to determine severity of the disease and prognosis.
=== Physiologically based Pharmacokinetics === Physiologically-Based Pharmacokinetic models integrate physiological information to simulate drug behavior in various tissues and organs. These models consider organ-specific blood flow, tissue permeability, and drug properties, facilitating predictions of drug concentration at specific sites. PBPK models are instrumental in understanding complex drug behaviors.
Vaxess Technologies, Inc. is a company started by a team of four graduate students from Harvard developing a suite of vaccines on the MIMIX sustained dermal delivery platform that combines high temperature stability, improved efficacy, and simplified delivery to improve global vaccine access.
Sources: en.wikipedia.org
Independent researchers estimate that between 300,000 and 500,000 civilians died during this period while the Bangladesh government puts the number of dead at three million, a figure now nearly universally regarded as excessively inflated. Some academics such as Rudolph Rummel and Rounaq Jahan say both sides committed genocide; others such as Richard Sisson and Leo E. Rose believe there was no genocide. In response to India's support for the insurgency in East Pakistan, preemptive strikes on India by Pakistan's air force, navy, and marines sparked a conventional war in 1971 that resulted in an Indian victory and East Pakistan gaining independence as Bangladesh. Yahya Khan was replaced by Zulfikar Ali Bhutto as president; the country worked towards promulgating its constitution and putting the country on the road to democracy. In 1972 Pakistan embarked on an ambitious plan to develop its nuclear deterrence capability with the goal of preventing any foreign invasion; the country's first nuclear power plant was inaugurated in that same year. India's first nuclear test in 1974 gave Pakistan additional justification to accelerate its nuclear program. Democracy ended with a military coup in 1977 against the leftist PPP, which saw General Zia-ul-Haq become the president in 1978. From 1977 to 1988, President Zia's corporatisation and economic Islamisation initiatives led to Pakistan becoming one of the fastest-growing economies in South Asia.
== History == The US Food and Drug Administration (FDA) approved lebrikizumab based on evidence from three clinical trials (J2T-DM-KGAB, J2T-DM-KGAC, and J2T-DM-KGAD) of 1,062 participants aged twelve years of age and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The three trials were randomized, double-blind, placebo-controlled, and parallel group studies. Two trials were designed to evaluate the efficacy and safety of lebrikizumab as a monotherapy and one trial was designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid treatment. The trials were conducted at 223 of sites in 16 countries including Australia, Bulgaria, Canada, Estonia, France, Germany, Latvia, Lithuania, Mexico, Poland, Singapore, South Korea, Spain, Taiwan, Ukraine, and the United States. The trials enrolled 508 participants in the United States and 554 participants outside the United States.
== Society and culture == Vaginal mesh kits were introduced to the U.S. market in 2004 through the U.S. Food and Drug Administration (FDA) pathway that did not require companies to demonstrate both safety and efficacy of the product if they were able to demonstrate that their product was similar to previous products already in the market. However, there was concern over reports of increased rates of postoperative complications over the next several years. That, in addition to the lack of available data that transvaginal mesh products were superior to other forms of surgical intervention and the expedited process which the vaginal mesh kits were introduced to the market, the FDA released a Safety Communication in 2011 that described serious complications associated with transvaginal mesh as "not rare". In 2019, the FDA ordered manufacturers to halt sales of transvaginal mesh intended for repair of pelvic organ prolapse. This does not include surgical mesh used during sacrocolpopexy, sacrohysteropexy, or transurethral sling procedures. Since 2008, a number of class action lawsuits have been filed and settled against several manufacturers of transvaginal mesh after people reported complications following surgery.
It was not long before Maximilien de Robespierre and the now dominant Jacobin Club turned against the radical factions of the National Convention, including the sans-culottes, despite their having previously been the strongest supporters of the revolution and its government. Several important leaders of the Enragés and Hébertists were imprisoned and executed by the very revolutionary tribunals they had supported. The execution of radical leader Jacques Hébert spelled the decline of the sans-culottes, and with the successive rise of even more conservative governments, the Thermidorian Convention and the French Directory, they were definitively silenced as a political force. After the defeat of the 1795 popular revolt in Paris, the sans-culottes ceased to play any effective political role in France until the July Revolution of 1830.
Sources: en.wikipedia.org
=== Weak base and weak coordinating anion === As perchloric acid is one of the strongest mineral acids, perchlorate is a very weak base in the sense of Brønsted–Lowry acid–base theory. As it is also generally a weakly coordinating anion, perchlorate is commonly used as a background, or supporting, electrolyte.
Daniel Roy Gilchrist Noboa Azín ( noh-BOH-ə; Latin American Spanish pronunciation: [daˈnjel noˈβo.a]; born 30 November 1987) is an Ecuadorian politician and businessman serving as the 48th and current president of Ecuador since 2023. Having first taken office at the age of 35, he is the second-youngest president in the country's history, after Juan José Flores, and the youngest to be elected. Noboa was a member of the National Assembly of Ecuador from 2021 until 2023 when it was dissolved following the muerte cruzada constitutional mechanism invoked by President Guillermo Lasso. Before his political career, Noboa served in several positions at Noboa Corporation, an exporting business founded by his grandfather. Noboa's father, Álvaro Noboa Pontón, unsuccessfully ran for president of Ecuador five times. He has been widely described as an heir to his family's companies and fortune. In May 2023, Noboa announced his candidacy for president in the 2023 snap election, running on the National Democratic Action ticket. He advanced to the run-off election in October, facing Luisa González, which many interpreted as an upset given his low polling numbers in the days leading up to the election. Noboa went on to win nearly 52% of the vote in the run-off, defeating González on 15 October 2023. He was re-elected to a full four-year term in the runoff of the 2025 presidential election, defeating González again with an improved margin.
Administratively headquartered in 29 floors of the U.S. Steel Tower in Pittsburgh's Central Business District, UPMC operates as a complete and integrated health provider system that, although legally separate from the University of Pittsburgh, identifies it as a supported organization in its articles of incorporation and remains closely affiliated with the university and its Schools of the Health Sciences including via the existence of mutual board memberships and subsidization of the university's academic programs. Under a collaborative and coordinated decision-making model, UPMC oversees all clinical activity, including a consolidated physicians' practice plan consisting of university faculty, while the University of Pittsburgh remains the guardian of all academic priorities, particularly faculty-based research. UPMC's 24-member Board of Directors equally splits representation between three groups: the University of Pittsburgh, the community at-large, and individuals historically involved in the governance of its system's hospitals. UPMC is composed of three major operating components: Provider Services, Insurance Services, and International and Commercial Services. The latter two divisions include the for-profit health insurance company (UPMC Health Plan) and a for-profit International and Commercial Services Division that seeks to bring health care, management, and technologies to market throughout the world. UPMC is the largest employer in the state of Pennsylvania.
== Pharmacology == Similar to other benzodiazepines clotiazepam has anxiolytic, sedative, hypnotic, amnesic, anticonvulsant and muscle relaxant pharmacological properties. Clotiazepam binds to the benzodiazepine site of the GABAA receptor where it acts as a full agonist; this action results in an enhanced GABA inhibitory effect at the GABAA receptor which results in the pharmacological effects of clotiazepam. Clotiazepam has a short elimination half-life and is less prone to accumulation after repeated dosing compared to longer-acting benzodiazepine agents. It is metabolised via oxidation. Clotiazepam is metabolised to hydroxy-clotiazepam and desmethyl-clotiazepam. After oral ingestion of a single 5 mg dose of clotiazepam by three healthy volunteers the drug was rapidly absorbed. The elimination half-life of the drug and its metabolites range from 6.5 hours to 18 hours. Clotiazepam is 99 percent bound to plasma protein. In elderly men the elimination half-life is longer and in elderly women the volume of distribution is increased. Individuals with liver impairment have a reduced volume of distribution as well as a reduced total clearance of clotiazepam; renal impairment does not affect the kinetics of clotiazepam. The dose equivalent to 10 mg diazepam is thought to be between 5 and 10 mg clotiazepam.
==== Cytochrome P450 modulation ==== It has been reported that bicalutamide may have the potential to inhibit the enzymes CYP3A4 and, to a lesser extent, CYP2C9, CYP2C19, and CYP2D6, based on in vitro research. However, no relevant inhibition of CYP3A4 has been observed in vivo with bicalutamide at a dose of 150 mg (using midazolam as a specific marker of CYP3A4 activity). In animals, bicalutamide has been found to be an inducer of certain cytochrome P450 enzymes. However, dosages of 150 mg/day or less have shown no evidence of this in humans. Bicalutamide has been identified as a strong CYP27A1 (cholesterol 27-hydroxylase) inhibitor in vitro. CYP27A1 converts cholesterol into 27-hydroxycholesterol, an oxysterol that has multiple biological functions including direct, tissue-specific activation of the ER (it has been characterized as a selective estrogen receptor modulator) and the liver X receptor. 27-Hydroxycholesterol has been found to increase ER-positive breast cancer cell growth via its estrogenic action, and hence, it has been proposed that bicalutamide and other CYP27A1 inhibitors may be effective as adjuvant therapies to aromatase inhibitors in the treatment of ER-positive breast cancer. In addition to CYP27A1, bicalutamide has been found to bind to and inhibit CYP46A1 (cholesterol 24-hydroxylase) in vitro, but this has yet to be assessed and confirmed in vivo.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.